Have you joined us at a Gathering HOPE event? We first introduced this monthly social/support gathering in Fall 2021 and it has become one of our most popular programs. Dozens of lung cancer community members join us on the [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
Author: Dr. Jennifer K. Renshaw, OTD, OTR/L, OTA/L Cancer treatment can make you tired which can make it harder to enjoy leisure activities and complete daily tasks. “Energy conservation” includes tips and tricks for you that use energy in [...]
Heath equity is a popular topic these days, but the concept is more than just a trendy phrase. In general, the health care system in the United States distributes services inefficiently and unevenly across populations which causes some Americans [...]
Question: I have a family history of lung cancer – both my mother and grandmother were diagnosed with the disease. Am I at greater risk for lung cancer because of genetics? The role that genetics plays in determining [...]
A popular way to talk about the incredible progress that has been made in lung cancer treatments over the past few years is to share the statistic that more lung cancer treatments have been approved in the past three [...]
Question: My doctors have determined that my lung cancer is progressing on its current targeted therapy and want to do another biopsy. Why would I need another biopsy since we already know the biomarker type? If I do need [...]
It can be hard to know where to go with your questions about lung cancer risk, diagnosis and treatment or how to connect with others who have had similar experiences. GO2’s HelpLine staff is here to help! You can [...]
FOR IMMEDIATE RELEASE November 14, 2022 Contact: Julia Spiess Lewis julia@perrycom.com 916-601-8282 GO2 for Lung Cancer Honors Champions of the Lung Cancer Community at [...]
On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA [...]